Zimmer Biomet Holdings (ZBH) Has a New Rating from Raymond James


Zimmer Biomet Holdings (ZBH) received a Buy rating and a $170.00 price target from Raymond James analyst Lawrence Keusch today. The company’s shares closed last Wednesday at $148.74.

According to TipRanks.com, Keusch is a 4-star analyst with an average return of 8.7% and a 71.9% success rate. Keusch covers the Healthcare sector, focusing on stocks such as Baxter International, Intuitive Surgical, and Becton Dickinson.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zimmer Biomet Holdings with a $163.44 average price target, representing a 7.9% upside. In a report issued on December 9, Needham also maintained a Buy rating on the stock with a $168.00 price target.

See today’s analyst top recommended stocks >>

Zimmer Biomet Holdings’ market cap is currently $31.48B and has a P/E ratio of -198.50. The company has a Price to Book ratio of -7.78.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet Holdings was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts